Indapamide retard in complex therapy of patients with chronic heart failure and arterial hypertension
Aim. To investigate indapamide retard effects on clinico-laboratory parameters and clinical course in patients with Functional Class (FC) II-IV chronic heart failure (CHF) and arterial hypertension (AH). Material and methods. The study included 60 patients (33 men and 27 women) with FC II-IV CHF and...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2010-04-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2037 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250438853951488 |
|---|---|
| author | S. N. Tereshchenko N. A. Dzhaiani A. E. Akimov N. A. Gnidkina A. G. Kochetov |
| author_facet | S. N. Tereshchenko N. A. Dzhaiani A. E. Akimov N. A. Gnidkina A. G. Kochetov |
| author_sort | S. N. Tereshchenko |
| collection | DOAJ |
| description | Aim. To investigate indapamide retard effects on clinico-laboratory parameters and clinical course in patients with Functional Class (FC) II-IV chronic heart failure (CHF) and arterial hypertension (AH). Material and methods. The study included 60 patients (33 men and 27 women) with FC II-IV CHF and AH; mean age 65,9±1,7 years. All participants were divided into two groups: Group I (n=30) received standard CHF therapy only, Group II (n=30) received standard CHF therapy plus indapamide retard (1,5 mg/d) for 6 months. The dynamics of CHF FC, blood pressure (BP), laboratory parameters, and adverse effect (AE) prevalence were assessed. Results. Indapamide retard therapy was associated with a significant reduction in CHF FC and improved left ventricular ejection fraction. In controls, the results of the 6-minute walk test increased from 299,4±18,8 to 338,4±32,5 m (р>0,05), while in patients receiving indapamide retard, they increased from 288,7±19,2 to 354,6±22,7 m (р=0,031). Positive dynamics of 24-hour BP monitoring parameters was more manifested in the indapamide retard group. After 6 months, NT-pro-BNP level significantly decreased in Group II, but not in Group I. Indapamide retard therapy was not associated with AE, and renal function or glycemia parameters were not affected. Conclusion. Adding indapamide retard to standard treatment of the patients with CHF and AH demonstrated good antihypertensive effects, improved CHF course, and minimal risk of AE. |
| format | Article |
| id | doaj-art-1a9bb671e67e4aa5b4db18580eee2f5c |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2010-04-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-1a9bb671e67e4aa5b4db18580eee2f5c2025-08-20T03:57:17Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252010-04-019243471749Indapamide retard in complex therapy of patients with chronic heart failure and arterial hypertensionS. N. Tereshchenko0N. A. Dzhaiani1A. E. Akimov2N. A. Gnidkina3A. G. Kochetov4Russian Cardiology Scientific and Clinical Complex; Moscow State Medico-Stomatological UniversityMoscow State Medico-Stomatological UniversityMoscow State Medico-Stomatological UniversityMoscow State Medico-Stomatological UniversityRussian State Medical University. MoscowAim. To investigate indapamide retard effects on clinico-laboratory parameters and clinical course in patients with Functional Class (FC) II-IV chronic heart failure (CHF) and arterial hypertension (AH). Material and methods. The study included 60 patients (33 men and 27 women) with FC II-IV CHF and AH; mean age 65,9±1,7 years. All participants were divided into two groups: Group I (n=30) received standard CHF therapy only, Group II (n=30) received standard CHF therapy plus indapamide retard (1,5 mg/d) for 6 months. The dynamics of CHF FC, blood pressure (BP), laboratory parameters, and adverse effect (AE) prevalence were assessed. Results. Indapamide retard therapy was associated with a significant reduction in CHF FC and improved left ventricular ejection fraction. In controls, the results of the 6-minute walk test increased from 299,4±18,8 to 338,4±32,5 m (р>0,05), while in patients receiving indapamide retard, they increased from 288,7±19,2 to 354,6±22,7 m (р=0,031). Positive dynamics of 24-hour BP monitoring parameters was more manifested in the indapamide retard group. After 6 months, NT-pro-BNP level significantly decreased in Group II, but not in Group I. Indapamide retard therapy was not associated with AE, and renal function or glycemia parameters were not affected. Conclusion. Adding indapamide retard to standard treatment of the patients with CHF and AH demonstrated good antihypertensive effects, improved CHF course, and minimal risk of AE.https://cardiovascular.elpub.ru/jour/article/view/2037chronic heart failurearterial hypertensionindapamide retard |
| spellingShingle | S. N. Tereshchenko N. A. Dzhaiani A. E. Akimov N. A. Gnidkina A. G. Kochetov Indapamide retard in complex therapy of patients with chronic heart failure and arterial hypertension Кардиоваскулярная терапия и профилактика chronic heart failure arterial hypertension indapamide retard |
| title | Indapamide retard in complex therapy of patients with chronic heart failure and arterial hypertension |
| title_full | Indapamide retard in complex therapy of patients with chronic heart failure and arterial hypertension |
| title_fullStr | Indapamide retard in complex therapy of patients with chronic heart failure and arterial hypertension |
| title_full_unstemmed | Indapamide retard in complex therapy of patients with chronic heart failure and arterial hypertension |
| title_short | Indapamide retard in complex therapy of patients with chronic heart failure and arterial hypertension |
| title_sort | indapamide retard in complex therapy of patients with chronic heart failure and arterial hypertension |
| topic | chronic heart failure arterial hypertension indapamide retard |
| url | https://cardiovascular.elpub.ru/jour/article/view/2037 |
| work_keys_str_mv | AT sntereshchenko indapamideretardincomplextherapyofpatientswithchronicheartfailureandarterialhypertension AT nadzhaiani indapamideretardincomplextherapyofpatientswithchronicheartfailureandarterialhypertension AT aeakimov indapamideretardincomplextherapyofpatientswithchronicheartfailureandarterialhypertension AT nagnidkina indapamideretardincomplextherapyofpatientswithchronicheartfailureandarterialhypertension AT agkochetov indapamideretardincomplextherapyofpatientswithchronicheartfailureandarterialhypertension |